B
KYNB

Bailard’s Kyntra Bio KYNB Stock Holding History

Bailard’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-261
Closed -$226K – 721
2021
Q1 		$226K Sell
261
-244
-48% -$260K 0.01% 622
2020
Q4 		$468K Sell
505
-141
-22% -$148K 0.02% 345
2020
Q3 		$664K Buy
646
+120
+23% +$129K 0.03% 251
2020
Q2 		$533K Hold
526
– – 0.03% 263
2020
Q1 		$457K Buy
526
+120
+30% +$119K 0.03% 240
2019
Q4 		$435K Buy
406
+46
+13% +$47K 0.02% 318
2019
Q3 		$333K Sell
360
-200
-36% -$220K 0.02% 379
2019
Q2 		$633K Buy
560
+240
+75% +$263K 0.04% 252
2019
Q1 		$435K Hold
320
– – 0.03% 329
2018
Q4 		$370K Hold
320
– – 0.03% 373
2018
Q3 		$486K Hold
320
– – 0.03% 382
2018
Q2 		$501K Sell
320
-80
-20% -$104K 0.03% 360
2018
Q1 		$462K Sell
400
-80
-17% -$105K 0.03% 335
2017
Q4 		$569K Buy
+480
New +$602K 0.04% 299

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bailard's KYNB Position: Q2 2021 in Review

Bailard sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 261 shares — an estimated $226K sold.

Bailard first reported a position in KYNB in Q4 2017 and held it in 14 quarters. The position peaked at $664K in Q3 2020. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Bailard reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Bailard sold 261 Kyntra Bio shares in Q2 2021, an estimated $226K.
  • Bailard first reported a position in Kyntra Bio in Q4 2017 and held it in 14 quarters.
  • Bailard's Kyntra Bio position peaked at $664K in Q3 2020.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Bailard's 13F filing for Q2 2021, filed 13 Aug 2021.